Shionogi combines 41% operating margins, high-margin ViiV royalties and Xocova PEP optionality with a discounted 9.2x–11.7x P/E despite the 2028–2030 HIV patent risk.
Overview
Shionogi is a research-driven Japanese pharmaceutical company with a differentiated mix of proprietary small molecules, hospital medicines, specialty therapies and high-margin ViiV royalties. Its Q1 FY2026 revenue rose **63.7% year over year to ¥163.31 billion**, beating consensus by 2.92%, while operating profit increased 90.6% to ¥66.91 billion and the operating margin reached 41.0%. Torii consolidation and the JT pharmaceutical absorption added immediate scale, including ¥24.2 billion of U.S. Radicava sales. Royalty income contributed ¥80.1 billion, led by ¥72.7 billion from ViiV’s HIV franchise. The key catalyst is **Xocova’s June 2026 FDA approval for COVID-19 post-exposure prophylaxis**, supported by a 67% reduction in symptomatic infection risk and a standalone profile without ritonavir drug interactions. Management reaffirmed FY2026 guidance of ¥700.0 billion revenue, ¥220.0 billion operating profit and ¥210.0 billion net income. Shares at ¥2,831–¥2,854 trade at roughly 9.2x–11.7x P/E versus 14.3x for Japanese pharma and 18.5x internationally, with a 2.55%–2.69% dividend yield. The valuation reflects the 2028–2030 ViiV patent risk, but the balance sheet, 66.7% equity ratio and 33%–41% margin profile support an attractive defensive-growth setup.